Efficacy of levocarnitine chloride (LC-80) in treatment of ischemic heart diseases by the serial multistage treadmill exercise testing. A multicenter double-blind group-comparison study.:A Multicenter Double-Blind Group-Comparison Study
スポンサーリンク
概要
- 論文の詳細を見る
The efficacy and overall safety of levocarnitine chloride (LC-80) in treatment of patientswith ischemic heart disease (effort angina, effort and rest angina, and silent myocardialischemia), were investigated, using serial multistage treadmill exercise test, and were comparedwith that of dilazep hydrochloride used as the control treatment, by the method ofmulticenter double-blind, group comparison study. The results obtained were as follows.<BR>1. The study comprised 166 patients, with 134 of them compared for efficacy, 166 for safety, and 112 for overall usefulness.<BR>2. Global improvement: "better than 'moderately improved' " was the finding in 45.6%of the levocarnitine chloride-treated group (LC group) and in 33.3% of the dilazephydrochloride-treated group (D group). There was no significant difference in globalimprovement between these two groups.<BR>3. Overall safety: no problem was observed in 95.0% of the LC group, and 95.3% of the D group.No patient in the LC group had to discontinue the test, but two patients inthe D group did so.<BR>4. Overall usefulness: "better than 'useful' " was the finding in 43.7% of the LC group andin 31.0% of the D group.In the X<SUP>2</SUP> test, no significant difference in overall usefulnessbetween these two groups was observed, but in the U test, significant difference wasnoted.<BR>5. Overall evaluation of the findings of exercise electrocardiogram: "better than 'moderatelyimproved'" was the finding in 46.3% of the LC group, and in 30. 3% of the Dgroup.There was no significant difference in overall evaluation of the findings ofexercise electrocardiogram between these two groups.<BR>6. The maximal exercise duration was prolonged in the LC group compared to pre-treatmentlevels, but in the D group such prolongation was not observed. However, therewas no significant difference in the maximal exercise duration between these two groups.<BR>7. The time to onset of the 1mm ST segment depression was significantly prolonged inthe LC group after the treatment. This prolongation was not observed in the D group.However, there was no significant difference in the time to onset of the 1mm ST segmentdepression between these two groups.<BR>8. The extent of ST depression after the treatment was significantly improved in the LCgroup, when compared at the same period of exercise, but there was no significantimprovement in the D group.There was no significant difference in the extent of STdepression after the treatment between these two groups.<BR>9. Side effects: four patients (5.0%) complained of side effects in the LC group, and fivepatients (5.8%) complained in the D group.But no severe case was reported.<BR>10. Abnormal laboratory findings: GOT and LDH levels increased in one case in the LCgroup ; on the other hand, CPK level increased in one case in the D group.Neitherwas clinically significant.<BR>The results suggested that the treatment with levocarnitine chloride (LC-80), administeredat a level of 1, 800 mg/day (in 3 doses), improved significantly the exercise tolerancecapability in patients with ischemic heart disease (effort angina, effort and rest angina, andsilent myocardial ischemia), and is as useful as, or more useful than dilazep hydrochloride.We concluded that levocarnitine chloride is a clinically useful drug for the treatment ofischemic heart disease.
- 一般社団法人 日本臨床薬理学会の論文
著者
-
長田 洋文
昭和大学藤が丘病院循環器内科
-
飯村 攻
札幌医科大学
-
中島 光好
浜松医科大学
-
蔵本 築
東京都老人医療センター
-
水野 康
藤田学園保衛大内科
-
蔵本 築
東京都老人医療セ
-
外畑 巌
藤田学園保健衛生大内科
-
新谷 博一
昭和大学
-
山崎 昇
浜松医科大学
-
戸嶋 裕徳
久留米大学
-
吉利 和
日本赤十字社医療センター
-
水野 康
藤田学園保健衛生大学内科
-
長田 洋文
昭和大学藤が丘病院内科
-
水野 康
藤田学園保健衛生大医学部内科
関連論文
- P813 器質的心疾患のない慢性心房細動における心房のRemodelingは加齢により修飾される
- 降圧前後の血圧概日リズムと自律神経調節に及ぼすカルシウム拮抗薬の作用について
- 高血圧患者への第2,3世代カルシウム拮抗薬投与法の時間薬理学的検討 : 至適薬剤投与時間と概日周期正常化について
- 実生活の中の老年学に向けて : 序論
- 本邦における循環器疾患の現況と対策
- 0329 HbAlcに基づいた耐糖能分類と循環器疾患死 : 第4次循環器疾患基礎調査(平成2年)に基づく予後調査成績(NIPPON DATA 90)より
- 0321 喫煙の循環器疾患死亡に及ぼす影響 : 1万人14年間の追跡調査より、NIPPON DATA
- 高血圧家族歴の治療への影響度--家族歴が濃厚であるとは (特集 高血圧診療のマクロとミクロ) -- (ミクロの高血圧診療)
- P338 新しいチトクロムP450 ω/ω-1 hydroxylase阻害薬のSHRにおける血圧降下作用の検討
- P277 Preconditioning(PC)による虚血心筋間質アデノシンレベルの変化とその意義 : microdialysis法による検討